AI in precision oncology
- Submission status
- Closed
- Submission deadline
The fields of cancer research and precision oncology are undergoing a massive transformation due to the application of artificial intelligence (AI). AI has enabled the detection of hidden patterns from multiple sources of information, including molecular profiling, pathology, and medical imaging, among others, as well as the integration of -omics data to provide a more comprehensive understanding of cancer. AI has also spurred the development of new assays for characterising cancer, prognostication, and predicting responses to specific treatments. These advances in tailoring treatment to the unique characteristics of a patient's cancer are a significant breakthrough. Despite the many opportunities that AI offers, challenges arise when translating these new tools from research settings to clinical practice.
The purpose of this Collection is to disseminate the most recent research and advancements in all facets of AI in cancer research, including basic, translational, and clinical studies. Additionally, the Collection seeks to provide a comprehensive review of the current applications of AI in precision oncology and offer expert insights on how to expedite AI tools from the laboratory to the clinic, with the ultimate goal of improving patient care. The Collection will prioritise articles which are using innovative methods, address a relevant real-world problem and at the same time provide high-quality evidence using multicentric datasets.
The topics will include, but are not limited to:
- Prognostic and predictive biomarkers in cancer
- Molecular profiling (genomics, transcriptomics, proteomics)
- Digital pathology
- Medical imaging
- Real-world data analysis
- Multimodal data integration
- Novel clinical trial designs
This is a joint collection between npj Precision Oncology and npj Breast Cancer. Topics of particular interest for npj Breast Cancer include:
- AI systems for breast cancer diagnosis
- AI systems for lymph node metastasis detection
- Automation of the assessment of immunohistochemical biomarkers
- HER2 and HER2-Low assessment
- Tumour infiltrating lymphocytes and tumour microenvironment
- Inference of breast cancer biomarkers from H&E-stained slides
- Multimodal biomarkers
This Collection supports and amplifies research related to SDG 3.
Editors
-
Raquel Perez-Lopez
Team Leader, Radiomics Group, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
-
Jorge S. Reis-Filho
Director, Experimental Pathology and of the Experimental Pathology Fellowship Program Affiliate Member, Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY, USA
-
Jakob Nikolas Kather
Professor, Technical University of Dresden, Dresden, Germany
-
Fiona Kolbinger
Surgical clinician scientist, National Center for Tumor Diseases, University Hospital Else Kroener Fresenius Center for Digital Health in Dresden, Dresden, Germany
This is a joint collection between npj Precision Oncology and npj Breast Cancer.
All articles have undergone the submitting journal's standard peer review process and have been subject to the submitting journal’s standard policies. This includes the journals’ policy on competing interests.
Click here to view npj Precision Oncology’s Editorial policies, and here to view npj Breast Cancer’s Editorial policies.
The Editors declare no competing interests with the submissions which they have handled through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.
If accepted for publication, an article processing charge applies (with standard waiver policy).
To view the article processing charges for npj Precision Oncology, click here.
To view the article processing charges for npj Breast Cancer, click here.
If your institution or country has an open access agreement with Springer Nature, you may publish your article OA at no cost or in some cases with the costs partially funded (see details here).
All Collections are open for submissions from all authors – and not by invitation only – on the condition that the manuscripts fall within the scope of the Collection and of npj Precision Oncology and npj Breast Cancer more generally.
Manuscripts submitted to an open Collection may be considered unsuitable for inclusion, particularly if they fall outside the scope of the Collection. In such cases, the authors will be notified by the editorial office and their manuscript can be considered as a regular npj Precision Oncology or npj Breast Cancer submission.
The in-house editors of npj Precision Oncology and npj Breast Cancer reserve the right to assume responsibility for the management of a Collection at any stage.
